STOCK TITAN

Pasithea Therapeutics: Vivo reports 9.2M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. (KTTA) is the issuer in an amended beneficial-ownership report listing Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, at 9,202,561 shares, and Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, at 929,069 shares. Each named reporting person is listed at 9.99%.

The first reported position comprises 338,614 common shares and 8,863,947 shares issuable upon full exercise of pre-funded warrants; the Cayman position comprises 34,182 common shares and 894,887 warrant shares. The totals are stated without applying warrant provisions that block exercise if it would cause the holder or affiliates to exceed 9.99% of voting securities. Pasithea had 33,414,448 common shares outstanding as of August 12, 2026.

Reported beneficial ownership, Vivo Opportunity Fund Holdings, L.P. 9,202,561 shares The general partner, Vivo Opportunity, LLC, is also reported with this amount.
Reported beneficial ownership, Vivo Opportunity Cayman Fund, L.P. 929,069 shares The general partner, Vivo Opportunity Cayman, LLC, is also reported with this amount.
Common shares held by Vivo Opportunity Fund Holdings, L.P. 338,614 shares Component of its reported beneficial ownership.
Shares issuable under pre-funded warrants, Vivo Opportunity Fund Holdings, L.P. 8,863,947 shares Included in its reported beneficial ownership, without applying the blocking provisions.
Common shares held by Vivo Opportunity Cayman Fund, L.P. 34,182 shares Component of its reported beneficial ownership.
Shares issuable under pre-funded warrants, Vivo Opportunity Cayman Fund, L.P. 894,887 shares Included in its reported beneficial ownership, without applying the blocking provisions.
Reported ownership percentage 9.99% Reported for each of the four reporting persons.
Common shares outstanding 33,414,448 shares As of August 12, 2026.
pre-funded warrants financial
"shares of Common Stock issuable upon exercise of pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
blocking provisions technical
"without giving effect to the blocking provisions"
beneficially own regulatory
"may be deemed to beneficially own an aggregate"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership did Vivo report in KTTA?

Vivo Opportunity Fund Holdings, L.P. and its general partner are each reported with 9,202,561 shares, while Vivo Opportunity Cayman Fund, L.P. and its general partner are each reported with 929,069 shares. The amounts include shares issuable under pre-funded warrants.

What limits exercise of the KTTA pre-funded warrants?

The warrants cannot be exercised into common shares if the exercise would cause the holder or its affiliates to own more than 9.99% of KTTA's voting securities. The reported warrant-share amounts reflect full exercise without applying that blocking provision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





70261F202

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 338,614.00 shares of common stock, par value $0.0001 per share (the "Common Stock") of Pasithea Therapeutics Corp. (the "Issuer"), and (ii) 8,863,947.00 shares of Common Stock issuable upon exercise of pre-funded warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent is based on 33,414,448 shares of Common Stock outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 9, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 338,614.00 shares of Common Stock of the Issuer, and (ii) 8,863,947.00 shares of Common Stock issuable upon exercise of pre-funded warrants. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent is based on 33,414,448 shares of Common Stock outstanding as of August 12, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 9, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 34,182.00 shares of Common Stock of the Issuer, and (ii) 894,887.00 shares of Common Stock issuable upon exercise of pre-funded warrants. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percent is based on 33,414,448 shares of Common Stock outstanding as of August 12, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 9, 2026. The pre-funded warrants contain provisions preventing such warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G




Comment for Type of Reporting Person: The reported share amount represents an aggregate of (i) 34,182.00 shares of Common Stock of the Issuer, and (ii) 894,887.00 shares of Common Stock issuable upon exercise of pre-funded warrants. All securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P. The percent is based on 33,414,448 shares of Common Stock outstanding as of August 12, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on September 9, 2026. The pre-funded warrants contain provisions preventing these warrants from being exercised into shares of Common Stock, if such exercise would result in the holder or its affiliates obtaining greater than 9.99% of the Issuer's voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon full exercise of the pre-funded warrants, without giving effect to the blocking provisions.


SCHEDULE 13G



Vivo Opportunity Fund Holdings, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:11/16/2026
Vivo Opportunity, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
Date:11/16/2026
Vivo Opportunity Cayman, LLC
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:11/16/2026

Keep reading